Drug Trial Radar · NCT06616974
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
191
Planned (sponsor's estimate)
Start
Sep 4, 2024
Primary completion
Nov 24, 2026
Study completion Jan 5, 2027
Sponsor
- Lead sponsor
- Tectonic TherapeuticIndustry
- Sponsor type
- Industry
- First posted
- Sep 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 83 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
Conditions
- Pulmonary Hypertension
- Heart Failure With Preserved Ejection Fraction
Interventions
TX000045- Dose ADrug
The participants will receive a subcutaneous injection of Dose A of TX000045 every 2 weeks for 24 weeks.
TX000045- Dose BDrug
The participants will receive subcutaneous injection of Dose B of TX000045 every 4 weeks for 24 weeks where they will alternate between TX000045 and placebo every 2 weeks.
PlaceboDrug
The participants will receive a subcutaneous injection of placebo every 2 weeks for 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline in Pulmonary Vascular Resistance (PVR) in participants with a combined pre- and post-capillary pulmonary hypertension (CpcPH).Time frame: Baseline up to Week 24 post first dose
- Assess safety of TX000045 by the incidence of adverse events, adverse events of special interest and SAEs.Time frame: Baseline up to Week 30 post first dose
- Number of participants with abnormal laboratory values and/or adverse events that are related to treatment.Time frame: Baseline up to Week 30 post first dose
- Number of participants with treatment-related adverse events.Time frame: Baseline up to Week 30 post first dose
- Number of participants with changes in the physical examination findings.Time frame: Baseline to Week 30 post first dose
Locations
72 sites in 17 countries. Site status is shown where the registry gives one.
Phoenix
Phoenix, Arizona
Scottsdale
Scottsdale, Arizona
San Francisco
San Francisco, California
Santa Rosa
Santa Rosa, California
Aurora
Aurora, Colorado
Jacksonville
Jacksonville, Florida
Augusta
Augusta, Georgia
McDonough
McDonough, Georgia
Boise
Boise, Idaho
USA
Louisville, Kentucky
Baltimore
Baltimore, Maryland
Boston
Boston, Massachusetts
Minneapolis
Minneapolis, Minnesota
St Louis
St Louis, Missouri
Omaha
Omaha, Nebraska
New York
New York, New York
New York
New York, New York
Durham
Durham, North Carolina
Philadelphia
Philadelphia, Pennsylvania
Pittsburgh
Pittsburgh, Pennsylvania
York
York, Pennsylvania
Port Arthur
Port Arthur, Texas
Waco
Waco, Texas
Salt Lake City
Salt Lake City, Utah
United States
Norfolk, Virginia
Yerevan
Yerevan, Armenia
Yerevan
Yerevan, Armenia
Yerevan
Yerevan, Armenia
Camperdown
Camperdown, Australia
New Lambton
New Lambton, Australia
Camperdown
Camperdown, New South Wales, Australia
Macquarie
Macquarie, New South Wales, Australia
New Lambton
New Lambton, New South Wales, Australia
Sydney
Sydney, New South Wales, Australia
Wollongong
Wollongong, New South Wales, Australia
Chermside
Chermside, Queensland, Australia
Hobart
Hobart, Tasmania, Australia
Malvern
Malvern, Victoria, Australia
Austria
Vienna, Austria
Brussel
Brussels, Belgium
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.